|
Human papilloma virus infection
|
0.090 |
Biomarker
|
disease |
BEFREE |
The proportion of blood immune cells in patients with HPV infection was Th1, Th17, Th2, and Treg, with statistical significance (P < .05); the expression of TLR3 and TLR9 in HPV-infected cells was higher than that in negative control group, with statistical significance (P < .05); TLR3 was higher than TLR9, with no significant difference (P > .05); the expression of IL-2, TNF-alpha, IFN-beta in each group, TLR3, and TLR9 was higher than that in negative control group (P < .05).
|
31785031 |
2020 |
|
Human papilloma virus infection
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Further analysis showed that the risk of cancer was extremely pronounced in HPV/EBV, co-infection (p = 0.0141), implicating the possible interaction between TLR 9(-1486T/C) genotype and HPV infection in increasing cancer/pre-cancer risk.
|
31129425 |
2019 |
|
Human papilloma virus infection
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Also, it suggests that OPSCC may respond to HPV infection by increased expression of TLR9.
|
29416610 |
2018 |
|
Human papilloma virus infection
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Subjects with HPV infection and rs352140-GA + AA genotype within TLR9 gene have the highest cervical cancer risk, compared to no HPV infection participants with rs352140-GG genotype, OR (95 %CI) = 3.22 (1.68-4.81).
|
28497211 |
2017 |
|
Human papilloma virus infection
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The results showed that genotype TT in the -1486 locus of TLR9 was significantly associated with HPV infection (OR = 3.25, 95% CI 1.12-9.46), squamous intraepithelial cervical lesion (OR = 3.76, 95% CI 1.36-10.41), and uterine cervical neoplasm (OR = 5.30, 95% CI 1.81-15.55).
|
28819773 |
2017 |
|
Human papilloma virus infection
|
0.090 |
Biomarker
|
disease |
BEFREE |
In women with, but not those without, a positive response to E6, higher expression of TLR3 (hazard ratio: 1.2 [95% confidence interval: 1.04-1.39], p = 0.012), TLR7 (1.39 [1.14-1.7], p = 0.001), TLR8 (1.37 [1.11-1.69], p = 0.003), or TLR9 (1.53 [1.13-2.08], p = 0.006) was significantly associated with clearance, revealing an important link between innate and adaptive immunity in the control of HPV infections following periods of persistence.
|
25346143 |
2015 |
|
Human papilloma virus infection
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Presence of HPV infection with TLR9 2848 (rs352140) GA/AA genotype increased the risk of cervical cancer 13.8-fold compared with the GG genotype.
|
23816930 |
2013 |
|
Human papilloma virus infection
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between a single-nucleotide polymorphism (SNP) (rs5743836) in the promoter region of TLR9 (T1237C) and type-specific HPV infections.
|
23677790 |
2013 |
|
Human papilloma virus infection
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Messenger RNA expression of TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8 and TLR9 was measured by quantitative reverse transcription-PCR using human endocervical specimens, collected before and after viral acquisition, in a cohort well characterized for HPV infections.
|
20473890 |
2011 |